Sanofi cuts 466 jobs, all ties to new CV research

French drugmaker Sanofi is cutting 466 jobs as part of an R&D “reshuffle” that will also put an end to the company’s new research efforts in cardiology, Reuters reports.

A spokesperson said on June 19 the reorganization of Sanofi’s R&D department will allow the company to concentrate its research efforts on cancer, immunology, rare diseases and vaccines. While that means Sanofi is putting a halt to any new research in cardiology, its existing CV research programs will remain intact.

The 466 job cuts will be implemented on a voluntary basis, according to Reuters. Right now, Sanofi employs 15,000 R&D workers worldwide.

Read the story below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.